Business Context and Reporting Period
Company: NeoStem, Inc. (formerly Lisata Therapeutics, Inc. in metadata, but filing identifies NeoStem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: NeoStem operates a commercial autologous adult stem cell bank, focusing on the collection, processing, and long-term storage of stem cells. The company is developing a nationwide network of collection centers and holds an exclusive license for VSEL (very small embryonic-like) stem cell technology. The company has completed the "run-off" of its former extended warranty business as of March 31, 2007.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Revenues | $693 | $55,895 |
| Gross Profit | $693 | $54,642 |
| Operating Loss | $(2,523,638) | $(1,818,455) |
| Net Loss | $(2,527,189) | $(1,816,335) |
| Net Loss Per Share (Basic) | $(0.52) | $(0.73) |
| Cash and Cash Equivalents (End of Period) | $969,776 | $1,058,898 |
| Working Capital | $735,649 | N/A |
| Total Liabilities | $401,402 | N/A |
| Stockholders' Equity | $2,114,295 | N/A |
Cash Flow Summary (Q1 2008):
- Net cash used in operating activities: $(1,401,739)
- Net cash used in investing activities: $(2,379)
- Net cash provided by financing activities: $69,667
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped significantly from $55,895 in Q1 2007 to $693 in Q1 2008. The 2007 figure included residual revenue from the discontinued extended warranty business, which ceased recognition in March 2007. The 2008 revenue consists solely of minimal monthly stem cell storage fees.
- Increased Operating Loss: The net loss increased by approximately $711,000 (39%) year-over-year, driven primarily by a $651,200 increase in Selling, General, and Administrative (SG&A) expenses.
- Expense Composition: SG&A expenses rose 35% to $2.52 million. This increase was largely due to non-cash equity-based compensation (stock, options, and warrants) totaling $758,200. Cash-funded operating expenses actually decreased by 8% ($107,000) due to reductions in legal and investor relations fees, partially offset by increased staffing and marketing costs.
- Share Count: Weighted average common shares outstanding increased from 2,471,653 in Q1 2007 to 4,904,542 in Q1 2008, diluting earnings per share impact despite the higher absolute loss.
Guidance, Outlook, and Risks
- Capital Needs: Management intends to meet near-term cash requirements through financing activities, specifically an anticipated equity offering of over $1 million in the second quarter of 2008, or through acquisition/collaborative arrangements.
- Operational Outlook: The company is focusing on multi-physician practices. A new collection center with ProHEALTH Care Associates received a provisional license in January 2008, with launch activities underway. Revenues from this center are expected in Q2 2008. The company is evaluating the future of a Pennsylvania center due to poor performance.
- Risks and Contingencies:
- Liquidity Risk: The company has a history of net losses and relies on external financing. If capital raising efforts fail, expansion activities may be delayed or deferred.
- Revenue Uncertainty: Current revenues from stem cell banking are minimal. The business model relies on future regulatory approvals and market adoption of adult stem cell therapies.
- Equity Dilution: The company frequently issues stock and warrants to pay for services (consulting, legal, investor relations), which increases share count and dilution.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $970,000 cash balance against the burn rate of ~$1.4 million per quarter in operating cash usage.
- Financing Progress: Confirm the status of the anticipated Q2 2008 equity offering mentioned in management commentary.
- Revenue Realization: Monitor the ProHEALTH Care Associates partnership for actual revenue generation in Q2 2008 as projected.
- Equity Dilution: Review the impact of outstanding warrants (2.1 million shares) and options (1.8 million shares) on future capital structure.
- Related Party Transactions: Note the significant use of stock to settle obligations with consultants and executives (e.g., CEO salary paid in stock).